Search > Obesity
2000 Participants NeededMy employer runs this trial

Enicepatide for Obesity

(Enith1 Trial)

Recruiting at 27 trial locations
RS
Overseen ByReference Study ID Number: WC45725 https://forpatients.roche.com/
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Hoffmann-La Roche
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

Who Is on the Research Team?

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Are You a Good Fit for This Trial?

Inclusion Criteria

I am able and willing to take the study drug myself or with help if needed.
History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
My BMI is 30 or higher, or 27-29.9 with a weight-related health condition.

Exclusion Criteria

I have a history of diabetes or serious blood sugar problems.
I have had or plan to have surgery for obesity, except old liposuction or tummy tuck.
I have a serious problem with my stomach emptying properly.
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • Enicepatide

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Placebo Group

Group I: Arm 4: Enicepatide Dosing Regimen 3Experimental Treatment1 Intervention
Group II: Arm 3: Enicepatide Dosing Regimen 2Experimental Treatment1 Intervention
Group III: Arm 2: Enicepatide Dosing Regimen 1Experimental Treatment1 Intervention
Group IV: Arm 1: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.